Clostridioides (previously known as Clostridiumdifficile (C. difficile) is a key cause of healthcare-associated infections and poses a substantial public health threat that carries high morbidity and mortality rates, especially amongst affected elderly patients (>65 years). C. difficile infection (CDI) also places a considerable burden on healthcare systems worldwide, with up to one-third of patients who develop an initial episode of CDI subsequently going on to develop a recurrence.

While there is widespread scientific literature regarding CDI, there is still a need to better inform the wider medical community on the importance of recognizing the microbiome-mediated nature of CDI and how different treatment modalities available can help to resolve the condition and/or restore the gut microbiota to avoid recurrence.

We have prepared an exciting programme and we hope that this exchange will promote the dissemination of information and stimulate interesting live discussions that would ultimately improve the healthcare of our patients.

The webinars are free of charge and the official language of the course is English. We will cover the sessions on Twitter via @GMFHx and the hashtag #GMFHCoverage. We encourage you to join and actively contribute to the debate, wherever you are!


*The webinar course is supported with a grant from Ferring Pharmaceutical. The program of these webinars have been independently developed and approved by the European Society of Neurogastroenterology and Motility (ESNM) and its faculty members.


Check out the programme:

The gut microbiota
Tuesday March 29th | 16:00 – 17:00 (CET)

Chair: René van den Wijngaard, Amsterdam, The Netherlands

  • Importance of gut microbiota in Clostridioides difficile Infection
    Joël Doré, Paris, France
  • A patient’s perspective on C. difficile Gail P Attara, Gastrointestinal Society, Vancouver, Canada

Watch the replay of this session:

Introduction to Clostridioides difficile infection
April 26 | 16:00 – 17:00 (CEST)

Chair: Edoardo Savarino, Padova, Italy

  • Epidemiology and outcome of patients with Clostridioides difficile infection
    Patrizia Spigaglia, Rome, Italy
  • IBD and IBS: “good” patients for bad Clostridioides difficile infection?
    Harry Sokol , Paris, France

Watch the replay of this session:

Pathogenesis of CDI
May 31 | 16:00 – 17:00 (CEST)

Chair: Joël Doré, Paris, France

  • difficile as a model of dysbiosis: the role of microbiota and microbial metabolites
    Ben Mullish (rising star UEG 2021)
  • Overview on Clostridioides difficile infection pathogenesis
    Ed Kujiper

Followed by Q&A with all chairs and speakers

Clinical picture and testing of CDI
June 28 | 16:00 – 17:00 (CEST)

Chair: Aonghus Lavelle, Cork, Ireland

  • Clinical features of Clostridioides difficile infection (TBC)
  • Clostridioides difficile infection laboratory investigations: When and how Frédéric Barbut, Paris, France

Followed by Q&A with all chairs and speakers

In order to join the webinar, please register for the event (free of charge). Once registered you will receive a confirmation email with the dial-in information for the webinar.

Treatment options for CDI
September 6 | 16:00 – 17:00 (CEST)

Chair: Giovanni Barbara, Bologna, Italy

  • First-line management
    Nicola Petrosillo
  • Faecal Microbiota Transplantation (FMT)
    Gianluca Ianiro

Followed by Q&A with all chairs and speakers

Prevention of recurrence and re-infections
October 12 | 16:00 – 17:00 (CEST)

Chair: Daniel Pohl, Zurich, Switzerland

  • Management of recurrence of Clostridioides difficile infection
    Steven Johnson, Buies Creek, North Carolina, USA
  • Management of severe Clostridioides difficile infection
    Tariq Iqbal, Birmingham, United Kingdom

Followed by Q&A with all chairs and speakers


LAST SESSION! Click here to register 

Future perspectives, November 22, 2022, from 16:00 -17:00hrs (CET)

Chair:  Qasim Aziz, London, United Kingdom

  • Clinical view on C. diff management in the future, Ben Mullish, United Kingdom
  • Future developments in microbiome research, Ken Blount, United States

Followed by Q&A with all chairs and speakers